Eutropin S Pen Injection Adverse Reactions

Summary of the safety profile: The relatively frequently reported adverse reactions include gastrointestinal disorders (nausea, vomiting, etc.), general disorders and administration site conditions (injection site reactions, etc.), musculoskeletal and connective tissue disorders (arthralgia, etc.), nervous system disorders (headache, etc.) and skin and subcutaneous tissue disorders (pruritus, rash and urticaria, etc.).
Tabulated list of adverse reactions: see Table 3.

Click on icon to see table/diagram/image

Description of selected adverse reactions: Hypersensitivity: Occasionally skin rashes (urticarial or erythema), generalized pruritus, or redness, pain or burning at injection site may occur uncommonly. In these cases, Eutropin S Pen Inj. should be discontinued.
Endocrine system disorders: A state of hypothyroidism may be developed or exacerbated during Eutropin S Pen Inj. treatment. Since untreated hypothyroidism may interfere with the response to Eutropin S Pen Inj., the patients should have a periodic thyroid test and should be treated with thyroid hormone when indicated.
Skin: Monitor patients on somatropin therapy carefully for increased growth, or potential malignant changes, of preexisting nevi.
Immunogenicity: Eutropin has given rise to the formation of antibodies to growth hormone in approximately 3.3% (2 out of 60 patients) in Turner syndrome patients.
Other adverse reactions: Occasionally, edema, headache, loss of subcutaneous fat, microscopic hematuria may occur. Rarely, proteinuria, increase of CPK, myoglobin may occur. And papilloedema, dysopia, headache, nausea, and vomiting accompanied by intracranial hypertension were reported. When these symptoms occur, Eutropin S Pen Inj. should be discontinued or lowered dosage.